391 related articles for article (PubMed ID: 29856243)
1. Talking to patients about biosimilars.
Janjigian YY; Bissig M; Curigliano G; Coppola J; Latymer M
Future Oncol; 2018 Oct; 14(23):2403-2414. PubMed ID: 29856243
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Biosimilars in Oncology.
Camacho LH
Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
[TBL] [Abstract][Full Text] [Related]
4. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
5. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
6. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
[TBL] [Abstract][Full Text] [Related]
7. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
Kim WS; Ogura M; Kwon HC; Choi D
Future Oncol; 2017 May; 13(15s):17-29. PubMed ID: 28482701
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars: biologics that meet patients' needs and healthcare economics.
McCamish M; Yoon W; McKay J
Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
[TBL] [Abstract][Full Text] [Related]
10. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
11. The rise of oncology biosimilars: from process to promise.
Verrill M; Declerck P; Loibl S; Lee J; Cortes J
Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars in Dermatology - theory becomes reality.
Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars: what clinicians should know.
Weise M; Bielsky MC; De Smet K; Ehmann F; Ekman N; Giezen TJ; Gravanis I; Heim HK; Heinonen E; Ho K; Moreau A; Narayanan G; Kruse NA; Reichmann G; Thorpe R; van Aerts L; Vleminckx C; Wadhwa M; Schneider CK
Blood; 2012 Dec; 120(26):5111-7. PubMed ID: 23093622
[TBL] [Abstract][Full Text] [Related]
14. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.
Cazap E; Jacobs I; McBride A; Popovian R; Sikora K
Oncologist; 2018 Oct; 23(10):1188-1198. PubMed ID: 29769386
[TBL] [Abstract][Full Text] [Related]
15. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
Melosky B; Reardon DA; Nixon AB; Subramanian J; Bair AH; Jacobs I
Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars are coming: ready or not.
Zalcberg J
Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar biologic drugs: a new frontier in medical care.
Geynisman DM; De Velasco G; Sewell KL; Jacobs I
Postgrad Med; 2017 May; 129(4):460-470. PubMed ID: 28343424
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
